West Clinical Research — research payments reported

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$2,411,553	29
2024	Research	$172,551	19

Breakdown

Who paid Research payments · program years 2024–2025

Vertex Pharmaceuticals Incorporated $2,282,680 5 payments
Novartis Pharmaceuticals Corporation $122,964 4 payments
Indivior Inc. $110,955 23 payments
E.R. Squibb & Sons, L.L.C. $65,107 4 payments
Moderna TX, Inc. $2,398 12 payments

Studies the money was for Research payments · program years 2024–2025

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy $1,625,587 2 payments
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy $541,299 1 payment
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy $118,388 2 payments
A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of Indv-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder $110,955 23 payments
A Phase 3b, Open-label, Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine As Part of Multimodal Therapy for Acute Pain After Laparoscopic Procedures of the Intraperitoneal or Retroperitoneal Cavities or Arthroscopic Orthopedic Procedures $108,848 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease $47,386 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) $11,869 1 payment
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy? $6,946 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) $5,373 1 payment
A Randomized, Two-Arm, Placebo-Controlled, Participant, Investigator and Sponsor-Blinded, Proof-Of-Concept Study Investigating the Efficacy, Safety and Tolerability of Quc398 in Patients With Symptomatic Knee Osteoarthritis $4,576 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.